中心终点裁定在新生儿脓毒症试验中的作用与挑战——以ProSPoNS试验为例
本文介绍ProSPoNS试验研究者决定设立中心终点裁定委员会(CEAC)以明确主要结局。2023年8月17日至18日在MGIMS Sevagram召开的会议一致同意主要结局为「医生诊断的脓毒症」,包含脓毒症/PSBI,CEAC将采用四项标准判定。该决定与已批准方案保持一致,作者推荐在多中心复杂临床试验中采用CEAC指导作为金标准。
要点
- ProSPoNS试验主要结局明确为「医生诊断的脓毒症」,包含脓毒症/PSBI。
- CEAC由外部专家主持,成员包括试验统计师、微生物学家和全部站点主要研究者。
- CEAC采用四项标准判定「医生诊断的脓毒症」:血培养状态、脓毒症筛查状态、PSBI/非PSBI体征症状及每次疾病事件的临床病程。
核心结论
- 研究者一致同意「医生诊断的脓毒症」为主要研究结局,包含脓毒症/PSBI,使研究假设、主要目的与样本量估算三者对齐。
- 作者推荐在多中心复杂临床试验中采用CEAC指导作为金标准,以实现结局评估的一致性和准确性。
研究设计与样本
- 本文为ProSPoNS试验的方法学说明,作为2021年发表于Trials的方案补充,设立中心终点裁定委员会(CEAC)。
- CEAC由外部学科专家主持,成员包括试验统计师、微生物学家和全部站点主要研究者。
- 研究者会议于2023年8月17日至18日在印度瓦尔达Sevagram的MGIMS召开。
主要发现
- 已发表方案中研究假设和主要目的基于「脓毒症」,主要结局指定为脓毒症/PSBI,而样本量估算基于「医生诊断的脓毒症」。
- 研究者会议讨论后一致同意「医生诊断的脓毒症」为主要研究结局,包含脓毒症/PSBI。
- 该澄清与已批准的研究方案(方案编号5/7/915/2012版本3.1,日期2020年2月14日)保持一致。
关键数值与推荐
- CEAC采用四项标准判定「医生诊断的脓毒症」:血培养状态、脓毒症筛查状态、PSBI/非PSBI体征和症状、每次疾病事件的临床病程。
- 试验注册于印度临床试验注册中心(CTRI),注册号CTRI/2019/05/019197,注册日期2019年5月16日。
临床怎么用
- 作者推荐在多中心复杂临床试验中采用CEAC指导作为金标准,以实现结局评估的一致性和准确性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite progress in reducing the infant mortality in India, the neonatal mortality decline has been slower, necessitating concerted efforts to achieve Sustainable Development Goal-3. A promising strategy aiming to prevent neonatal sepsis in high-risk, vulnerable, low birth weight neonates through an innovative intervention includes probiotic supplementation. This article communicates the decision by the ProSPoNS trial investigators to establish a Central Endpoint Adjudication Committee (CEAC) as an addendum to the protocol published in Trials in 2021 for the purpose of clarifying the primary outcome. In the published protocol, the study hypothesis and primary objective are based on "sepsis," the primary outcome has been specified as sepsis/PSBI, whereas the sample size estimation was performed based on the "physician diagnosed sepsis." To align all the three above, the investigators meeting, held on 17th-18th August 2023, at MGIMS Sevagram, Wardha, deliberated and unanimously agreed that "physician diagnosed sepsis" is the primary study outcome which includes sepsis/PSBI. The CEAC, chaired by an external subject expert and members including trial statistician, a microbiologist, and all site principal investigators will employ four criteria to determine "physician diagnosed sepsis": (1) blood culture status, (2) sepsis screen status, (3) PSBI/non-PSBI signs and symptoms, and (4) the clinical course for each sickness event. Importantly, this clarification maintains consistency with the approved study protocol (Protocol No. 5/7/915/2012 version 3.1 dated 14 Feb 2020), emphasizing the commitment to methodological transparency and adherence to predefined standards. The decision to utilize the guidance of a CEAC is recommended as the gold standard in multicentric complex clinical trials to achieve consistency and accuracy in assessment of outcomes.Trial registrationClinical Trial Registry of India (CTRI) CTRI/2019/05/019197. Registered on 16 May 2019.
引用
- Sinha AP, Raja D, Mahajan KS, et al. Role of central endpoint adjudication and challenges in trials on neonatal sepsis-a case of ProSPoNS trial. Trials. 2024. PMID: 38970042. doi:10.1186/s13063-024-08298-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。